tbuckley/cabot-search huggingface dataset:
Outcome of FIGO stage I-II cervical cancer patients treated with intensity modulated pelvic radiation therapy
Authors: J. D. Kochanski, J. C. Roeske, L. K. Mell, S. D. Yamada, N. Mehta, A. J. Mundt
Journal: Journal of Clinical Oncology (2004)

5027 Background: Intensity modulated pelvic radiation therapy (IM-PRT) is receiving increasing attention in gynecology. Numerous investigators have shown that IM-PRT reduces the volume of normal tissues irradiated compared to conventional pelvic RT. Recent studies have noted less toxicity in pts receiving IM-PRT. No data, however, exist regarding tumor control using IM-PRT. We present our experience using IM-PRT in stage I-II cervical cancer. Methods: Between 2/00 and 2/03, 34 stage I-II cervical cancer pts received IM-PRT. 21pts (12 IB, 9 IIA-IIB) with an intact uterus underwent IM-PRT (20 received weekly cisplatin) followed by brachytherapy, and in 6, simple hysterectomy. 13 stage I pts underwent surgery and received IM-PRT due to adverse features (lymphatic invasion, tumor >4 cm, positive nodes). 6 also received chemotherapy and 2 brachytherapy. On a contrast-enhanced CT scan, a clinical target volume was contoured consisting of the upper vagina, parametria, uterus (if present), presacral and pelvic lymph nodes, and was expanded by 1 cm creating a planning target volume (PTV). IM-PRT plans were generated using inverse planning. Pts were followed with physical exams, cytology, and CT scans. Late toxicity was graded using the RTOG/EORTC scale. Results: IM-PRT plans were highly conformal, with excellent PTV coverage and considerable sparing of the small bowel, bladder and rectum. At a median follow-up of 26.4 months, 5 pts (15%) have recurred, for a 3-year actuarial disease-free survival of 82%. All 5 recurred in extra-pelvic sites. One pt (2.9%) recurred in the pelvis, for a 3-year actuarial pelvic control (PC) of 95%. This pt had stage IIB disease. The 3-year PC of pts with an intact uterus and those treated adjuvantly were 91% and 100%. No pt developed grade ≥ 2 gastrointestinal (GI) or genitourinary (GU) sequelae (2 had grade 1 GI and 1 grade 1 GU toxicity). Conclusions: Stage I-II cervical cancer pts treated with IM-PRT have an excellent tumor control and low rate of toxicity. These results represent the first outcome report of gynecology pts treated with IM-PRT. Larger numbers and longer follow-up are needed to confirm these encouraging results. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Varian, Inc.
The impact of treatment for osteosarcoma on long term survivors with therapy of increasing dosage and dose intensity
Authors: I. J. Cohen, S. Ash, Y. Goshen, E. Boneda, M. Berant, I. Meller, J. Isaakov, I. Buchvall, Y. Kollender, I. Yaniv
Journal: Journal of Clinical Oncology (2004)

8571
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
Authors: Ann-Lii Cheng, Gerardo H. Cornelio, Lin Shen, Timothy Jay Price, Tsai-Sheng Yang, Ik-Joo Chung, Guanghai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigette Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Cheung Yau, Frank Beier, Sudipto Chatterjee, Robert S.C. Lim
Journal: Journal of Clinical Oncology (2015)

566 Background: The Asia-Pacific, multicenter, nonrandomized, phase II APEC study previously reported that first-line therapy for pts with KRAS ex 2 wt mCRC consisting of C once every 2 weeks combined with FOLFOX or FOLFIRI achieved efficacy and safety profiles comparable to those reported in analogous pivotal studies involving weekly C. This final analysis presents OS data from the KRAS wt intent-to-treat (ITT) population, as well as subgroup efficacy analyses stratified by BRAF, PIKC3A, and all RAS mutation status. Methods: Eligible pts received C once every 2 weeks (day 1 of each cycle, 500 mg/m 2 ) with FOLFOX or FOLFIRI (investigator’s choice). Study treatment continued until disease progression, dose-limiting toxicity or consent withdrawal. The primary endpoint was best confirmed overall response as assessed by RECIST 1.0; progression-free survival (PFS) and OS were secondary endpoints. In the evaluable populations, the status of BRAF, PIK3CA, and all RAS mutations was assessed retrospectively by pyrosequencing. Results: 42 months after the last patient was enrolled, median OS in the KRAS wt population was 26.8 months (Table). There were no unexpected safety findings. Additional biomarker results—including objective response rate (ORR), PFS, and OS subgroup analyses stratified on BRAF, PIKC3A, and all RAS mutation status—will be presented. Conclusions: The observed median OS of 26.8 months in the KRAS wt population is comparable to that reported in prior pivotal studies involving weekly C plus FOLFOX or FOLFIRI in the first line. These results suggest that C plus FOLFOX or FOLFIRI in a once-every-2-weeks regimen is active and tolerable as first-line therapy in this Asia-Pacific study population and a convenient alternative to weekly administration. Clinical trial information: NCT00778830. [Table: see text]
Real-World Study on Oxaliplatin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms : Clinical Outcomes and Preliminary Correlation with Biological Factors
Authors: F. Spada, N. Fazio, R. Marconcini, A. Antonuzzo, S. Ricci, A. Fontana, G. Luppi, L. Antonuzzo, F. Di Costanzo, E. Nobili, D. Radice, S. Galdy, M.A. Sonzogni, E. Pisa, M. Barberis
Journal: Annals of Oncology (2014)
Combination chemotherapy with gemcitabine and cisplatin in patients with cytokeratin 7-positive/cytokeratin 20-negaive metastatic or unresectable adenocarcinoma of liver
Authors: G.-W. Lee, J. S. Jang, C. Suh
Journal: Journal of Clinical Oncology (2005)

4222 Background: Patients with metastatic or unresectable adenocarcinoma of liver face a particularly dismal prognosis, and no standard palliative chemotherapy has not been defined. The aim of our study is to evaluate the efficacy and safety of combination chemotherapy with gemcitabine and cisplatin in patients with cytokeratin 7-positive (CK 7(+))/cytokeratin 20-negaive (CK 20 (-)) metastatic or unresectable adenocarcinoma of liver. Methods: Between March 2002 and October 2004, a total of 21 patients with CK 7(+)/CK 20 (-) adenocarcinoma among 30 patients with biopsy proven adenocarcinoma of liver were entered in this study. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8 and cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks. Results: Six-two cycles of treatment were given, with a median of 3 cycles (range, 2–6 cycles). All patients were evaluable for response rate and toxicity profile. 5 patients had a partial response (PR), 11 patients had stable disease (SD) and 5 patients progressed during treatment. A median survival of 9.30 months (randge,6.43–12.17) was obtained, and median time to progression was 4.98 months (range,3.60–6.36). Hematologic and non-hematologic toxicities were generally acceptable. However, there was 1 treatment-related mortality caused by thrombotic thrombocytopenia purpura (TTP) asscociated with gemcitabine and cisplatin. Conclusions: The combination chemotherapy of gemcitabine and cisplatin showed modest effect and well tolerated treatment for patients with CK 7(+)/CK 20 (-) metastatic or unresectable adenocarcinoma of liver. However, Physicians should also be aware of TTP during and after course of combination chemotherapy with gemcitabine and cisplatin. No significant financial relationships to disclose.
Abstract 14667: Risk Profiles and Antithrombotic Treatment of Patients With Atrial Fibrillation in China: China Registry of Atrial Fibrillation (CRAF)
Authors: Yihong Sun, Dayi Hu
Journal: Circulation (2013)

Background: Limited data are available on the CHADS2, CHA2DS2-VASc score and management of antithrombotic therapy in atrial fibrillation (AF) patients in China. The objective of this study is to in...
Taxonomic congruence versus total evidence, and amniote phylogeny inferred from fossils, molecules, and morphology.
Authors: D J Eernisse, A G Kluge
Journal: Molecular Biology and Evolution (1993)

Taxonomic congruence and total evidence are competing paradigms in phylogenetic inference. Taxonomic congruence focuses on deriving a consensus from the results obtained from separately analyzed data sets, whereas total evidence uses character congruence in the search for the best-fitting hypothesis for all of the available character evidence. Explicit or implicit use of taxonomic congruence is usually employed when an investigator either has both molecular and morphological data sets or has different gene-, rRNA-, or protein-sequence data sets available. Indeed, a taxonomic congruence rationale is frequently used as the basis for exploring classes of data, thus allowing comparison between the phylogenetic signal emerging from a particular data set and those of other such classes. Problematic aspects of employing the taxonomic congruence approach include the potentially misleading and arbitrary choices of both a consensus method and the division of characters into subsets. If the goal of an analysis is to provide the best estimate of genealogy afforded by the available character evidence, then taxonomic congruence is substantially more arbitrary than a total evidence approach. The theoretical advantages of phylogenetic estimates based on total evidence are argued in the present study and are illustrated with an example of amniote relationships. We report conflicting results from total evidence and taxonomic congruence approaches, with analyses of previously reported data from both fossil and living amniotes and from both morphology and molecules, the latter including available 18S rRNA, 28S rRNA, and protein sequences. We conclude that a more highly resolved and robust phylogenetic hypothesis of amniotes, the traditional one, emerges when a total evidence approach is employed.
Cancer Registry Analysis of the first 200 cases seen at the Aga Khan Health Services, Tanzania (AKHST).
Authors: Amyn G. Alidina, Hamis Rajabu Ngakonda
Journal: Journal of Clinical Oncology (2015)

e12635 Background: Cancer data collection in Africa is difficult, given challenges with resourses, compliance and understanding. Methods: Cancer Registry Program was established in 2014 at the AKHST, a private, non-profit organization located in Dares Salaam. We analyzed our first 200 cases, and compared this with the regional cancer registry data to know the difference. Results: At AKHST, top three cancers in men were Prostate (27%), Colorectal (14%), and Non-Hodgkin’s Lymphoma (11%). Top three cancers in women were Breast (42%), Colorectal (12%), and Cervix Cancers (8%). Over 60% of all cancers were above the age of 50 years, and only 37% were below the age of 50 years. Carcinoma accounted for 72% of all cancers. AJCC staging showed 34% were Stage IV, 25% Stage III, 24% were Stage I and II; 17% not staged. At a short follow-up, 68% of patients are alive, 8% passed away, and 24% have moved out. Comparing this with the East African cancer registry data, top three cancers in men were Kaposi Sarcoma (17%), Prostate Cancer (15%), and Esophageal Cancer (8.4%). In women top three were Cervical Cancer (27%), Breast Cancer (20%) and Kaposi Sarcoma (6.5%). Younger age at diagnosis is reported, and over 70% of all cancer cases succumb to their disease. Lung Cancer, a common cancer worldwide, accounts for only 3% of all cancers in EA. Tobacco use in sub-Saharan Africa is relatively low, but is expected to rise over the next few decades. Conclusions: : Fewer Kaposi sarcoma, Esophageal Cancer and Cervical Cancers, than those seen the government centers in the region are likely the result of higher socio-economic status, better educational level and lower HIV related malignancies, seen in cancer cases at the AKHST. Our patients at diagnosis are older in age, and earlier in stage, appearing to have a drift towards that seen in the west. Early detection, prevention and screening in East Africa, remain the mainstay of future control of the potentially raising cancer epidemic expected in the decades ahead
Contraception and Pulmonary Embolism
Journal: New England Journal of Medicine (1971)

A brief comparison of the literature on thromboembolic complications of oral contraceptives is made with the increased mortality rate for nonpregnant females: (3.04 to 3.96 per 1,000,000) and decreased rate for males recently reported by Zimmerman, Adelson, and Ratnoff (New England Journal of Medicine, 1970). Assuming 15% of the population was using oral contraception, the increase in females means there is a fourfold increase in risk attributable to oral contraceptives. Since the number of cases was small, tests for significance would not be helpful in interpreting the data. The data indicate results similar to previously published information on contraceptive pills. The author's conclusion that the impact of oral contraceptives is "not dramatic" may be misleading.
The Health Care Consequences Of Australian Immigration Policies
Authors: John-Paul Sanggaran, Bridget Haire, Deborah Zion
Journal: PLoS Medicine (2016)

Points• In Australia, immigration policy is to incarcerate those seeking asylum in order to deter others from coming.• Within this environment, health care providers frequently experience "dual loyalty" conflict, whereby they cannot serve the interests of both their patients and their employers.• The ratification of the Optional Protocol to the Convention Against Torture (OPCAT) would allow for domestic and international monitoring of places of detention, which would serve to ameliorate some of the most problematic aspects of the detention system, including the undemocratic lack of transparency.• This would assist in resolving the "dual loyalty" conflict that health care workers must contend with in the current situation.
Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation
Authors: E Holler, HJ Kolb, E Hiller, W Mraz, W Lehmacher, B Gleixner, C Seeber, U Jehn, HH Gerhartz, G Brehm
Journal: Blood (1989)
Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions
Authors: William V. Tamborlane, Morey W. Haymond, David Dunger, Ravi Shankar, Rose Gubitosi-Klug, Kathleen Bethin, Janina Karres, Paolo Tomasi, Ingrid Libman, Paula H. Hale, Ronald Portman, Georgeanna Klingensmith, Michael Reed, Jeffrey Blumer, George Giacoia
Journal: Diabetes Care (2016)

The Best Pharmaceuticals for Children Act of 2002 mandated that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) carries out critical reviews of the gaps in knowledge and unmet needs regarding safe and effective pharmacologic treatment of infants, children, and adolescents in a broad range of disease areas.In 2012, NICHD selected diabetes mellitus as one of the pediatric disorders for review.
Abstract 19281: Chemokine-Coupled β2 Integrin-Dependent mRNA Stabilization in Macrophages Modulates VEGF-A Protein Levels During Ischemia-Induced Arteriogenesis
Authors: Alan R Morrison, Timur O Yarovinsky, Bryan D Young, Filipa Moraes, Tyler Ross, Nicolle Ceneri, Jiasheng Zhang, Zhen W Zhuang, Albert J Sinusas, Martin A Schwartz, Michael Simons, Jeffrey R Bender
Journal: Circulation (2013)

VEGF-A directs both developmental and inducible arteriogenesis through the maturation of smaller vessels and the recruitment of collateral networks. Our lab has demonstrated that integrin-induced mRNA stability plays an important role in macrophage production of VEGF-A protein through translocation and activation of the mRNA stabilizing protein, HuR. It is well known that macrophages may serve as a source of VEGF-A; however, it remains unclear whether macrophages are the principle source of VEGF-A during ischemia-induced arteriogenesis and whether this integrin signaling mechanism modulates VEGF-A protein levels in ischemic muscle tissue in vivo. Here we demonstrate that chemokine-coupled β2 integrin adhesion signaling results in the formation of a complex between the low molecular weight G-protein, Rac2, and the heavy chain of Nonmuscle Myosin IIA (MyH9), leading to translocation of the message stabilizing protein, HuR, and the subsequent prolongation of VEGF-A mRNA half-life. Macrophage-specific gene deletion of MyH9 reduces chemokine-coupled β2 integrin adhesion-stimulated HuR translocation and consequent stabilization of VEGF-A message. Moreover, during hindlimb ischemia, there is global loss of VEGF-A protein in the arteriogenic muscle tissue along with decreased perfusion recovery secondary to decreased small vessel arteriogenesis in the macrophage-specific MyH9-/- mice. These defects appear specific to the induced inflammatory response as these mice demonstrate adequate capillary angiogenic, arteriogenic and arteriolar collateral development at baseline. This chemokine-coupled, adhesion-based signaling pathway provides a unique, rapid molecular switch in gene expression whereby inflammatory monocyte-derived macrophages become the key in vivo source of VEGF-A protein during ischemia-induced arteriogenesis. We anticipate this pathway to be a novel target for the therapeutic induction or inhibition of VEGF-A-mediated arteriogenesis where clinically relevant.
CD56+ Clonal Plasma Cells In Multiple Myeloma Are Associated With Unique Disease Characteristics and Have a Counterpart Of CD56+ Normal Plasma Cells With Increased Maturity
Authors: Bruno Paiva, Martin Perez-Andres, Maria Laura Gutierrez, Karen Dybkaer, Ana Rasillo, Maria Dolores Tabernero, Antonio Lopez, Fedor Kryukov, Paloma Carrasco, Maria Luz Sanchez, Laura Rosiñol, Joaquin Martinez Lopez, Consultant, Albert Oriol, Felipe de Arriba, Luis Palomera, Enrique Bengoechea, Juan Jose Lahuerta, Joan Blade, Alex Schmitz, Hans E Johnsen, Jesús F San Miguel, Alberto Orfao
Journal: Blood (2013)
Abstract 19: Fibrinogen Gamma-Chain Peptide-Coated, Adenosine Diphosphate-Encapsulated Liposomes Rescue Lethal Blast Lung Injury Hemorrhage via Purinergic Signaling
Authors: Kohsuke Hagisawa, Hiroki Miyawaki, Manabu Kinoshita
Journal: Circulation (2014)

Background: Fibrinogen gamma-chain (HHLGGAKQAGDV, H12)-coated, adenosine-diphosphate (ADP)-encapsulated liposomes [H12-(ADP)-liposomes] that accumulate at bleeding sites via interaction with activated platelets via GPIIb/IIIa and release ADP. Objective: To elucidate the effect of H12-ADP-liposomes and its mechanisms on the lethal pulmonary hemorrhage following blast injury. Methods: Mice were pretreated with H12-ADP-liposomes (n=14), ADP-liposomes (n=10), PBS-liposomes (n=10) or normal saline (n=14). A single shot of laser induced shock wave (LISW, 1.8 J/cm2) caused lethal diffuse alveolar hemorrhage in mice. Furthermore, to examine the adenosine effect of H12-ADP-liposomes, adenosine A2A receptor antagonist (ZM241385, n=6) or adenosine A2B receptor antagonist (PSB 1115, n=6) was administered 1 hr before the H12-ADP-liposomes + LISW procedures. Among them, the acute prognosis (survival rates) and pathological injury score (blending area) were compared. The levels of albumin and MIP-2 in the bronchoalveloral lavage fluid (BALF) were measured after LISW in each group. Results: H12-ADP-liposomes significantly improved mouse survival (Figure) and reduced the pathological injury score than normal saline (35 vs 40, p=0.004, n=5). H12-ADP-liposomes reduced the albumin leakage (0.8 vs 1.3 mg/ml, p=0.03, n=6) and MIP-2 levels in the BALF (74 vs 355 pg/ml, p&lt;0.01, n=6) than normal saline. Adenosine receptor (especially A2B) antagonists prevented from rescuing and reducing the BALF albumin and MIP-2 leakage by the H12-ADP-liposomes treatment. Conclusions: H12-ADP-liposomes may be effective for acute blast lung injury, functioning hemostasis and organ protection via anti-inflammatory purinergic signaling.
Evaluation of previous product residue on magnetic bar used for manufacturing of Japanese Encephalitis vaccine
Authors: Ratiya Kukhetpitakwong, Worawit Sangamrum, Kornkaew Laima, Tassanee Damriram, Tulyaluck Aupaichit, Karuna Tuncharoen, Boonrak Thawornrungroaj
Journal: Asian Journal of Pharmaceutical Sciences (2015)
The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL)
Authors: M. S. Kaminski, D. Hamstra, J. Estes, R. Wahl
Journal: Journal of Clinical Oncology (2006)

7509 Background: The FLIPI is potentially useful in predicting clinical outcome and comparing treatment results among clinical studies in FL. We recently reported the results of I-131 tositumomab as frontline treatment in 76 pts with advanced-stage FL (NEJM 325:441, 2005). A single 1-week course resulted in a 95% and a 75% overall and complete response (CR) rate, respectively, and at a median follow-up of 5.1 years median progression-free survival (PFS) was 6.1 yrs. In multivariate analyses, bone marrow involvement was the only baseline variable that had a significant effect on PFS. Methods: To evaluate whether baseline FLIPI scores in this study could predict outcome and to compare this pt population with that in other frontline studies, the records of all 76 patients were reviewed. Results: FLIPI scores were available for 74 of the 76 pts: 11 pts (15%) low risk, 37 (50%) intermediate risk, and 26 (35%) high risk. CR rates for each risk group were 82%, 73%, and 73%, respectively. 5-yr PFS were 63% (35–92%, 95% CI), 63% (47–78%), and 52% (33–71%), respectively, p = 0.322. Grouping low + intermediate risk vs. high for PFS: p = 0.134. 5-yr overall survival (OS) rates were 100%, 95% (87–100%), 78% (62– 93%), respectively, p = 0.072, but grouping low + intermediate risk vs. high p = 0.028. A comparison to other frontline studies is below. Conclusions: The FLIPI did not predict for PFS or OS in FL pts treated with single-agent I-131 Tositumomab. However, an OS difference was seen when low + intermediate risk pts were grouped and compared with high risk pts. The distribution of FLIPI scores amongst pts in this study is similar to that observed in other front-line FL studies. Further studies exploring single-agent radioimmunotherapy vs. chemo/radioimmunotherapy combinations are warranted. [Table: see text] [Table: see text]